In breast cancer, abnormal expression of LMO4 could enhance the transforming growth factor-β (TGF-β) signaling pathway and may promote breast cancer progression by regulating epithelial–mesenchymal transformation (EMT) regulated by TGF-β [25]. This evidence concerns the gene TGFB1 and breast cancer.